Our Future Health (OFH)
Our Future Health is a prospective, observational cohort study of the general adult population of the United Kingdom (UK). The programme aims to recruit up to 5 million adults (18 years and older) living in the UK, and so far (December 2025) includes over 1,929,000 participants who have completed baseline health questionnaires. Recruitment began in July 2022, with a focus on enrolling historically underrepresented populations in health research. Participants are routinely followed up through linkage to health and health-related data and recontacted for ongoing biological sampling and questionnaires.
Study design
Cohort - research programme, Cohort - open
Number of participants at first data collection
1,929,752 (participants as of December 2025)
Recruitment is ongoing
Age at first data collection
≥ 18 years (participants)
Participant year of birth
Varied (participants)
Participant sex
All
Representative sample at baseline?
No
Sample features
Countries
Year of first data collection
2023
Primary Institutions
National Health Service (NHS) (Healthcare/Medical, United Kingdom)
Our Future Health (Third Sector, United Kingdom)
Profile paper DOI
Not available
Funders
Alnylam Pharmaceuticals, Inc. (Industry, United States of America)
Amgen Inc. (Industry, United States of America)
Asthma + Lung UK (Third Sector, United Kingdom)
AstraZeneca (Industry, United Kingdom)
Biogen Inc. (Industry, United States of America)
Ongoing?
Yes
Data types collected
- Physical or biological assessment (e.g. blood, saliva, gait, grip strength, anthropometry)
- Secondary data
- Self-completed questionnaire – online
- None
- None
- Healthcare data
- Mortality data
Engagement
Keywords
